On Tuesday (June 19) two Canadian cannabis companies gave their shareholders a progress update on their respective expansions for Australian ventures.

The Australian cannabis market has grown at a remarkable pace so far in 2018 with multiple Canadian companies announcing expansions into the jurisdiction.

This market is currently only legal for medical cannabis with the patient population estimated at over 30,000  according to research firm Deloitte in 2016.

Cronos offers licensing update for Australian division

Cronos Group (NASDAQ:CRON,TSX:CRON) shared with its shareholders the Australian joint venture created earlier this year by the company, named Cronos Australia, obtained a manufacturing license from the Australian Office of Drug Control.

The license increased the offerings of Cronos Australia as the company can now legally manufacture cannabinoid-based products.

“This is a key step for expanding our research and product development while also allowing us to produce the full scope of cannabis products for the region,” Mike Gorenstein, CEO of Cronos Group said in a statement.

Rodney Cocks, CEO of the Australian division, said he sees the venture in a solid position to even expand its outreach and export cannabis product to New Zealand and the Southeast of Asia.

Cronos’ Canadian stock finished the day C$9.11 per share, a 2.13 percent increase from its previous close, while the company’s Nasdaq shares have risen 1.18 percent to reach a US$6.86 price per share.

On the analyst research aggregator site TipRanks, Cronos’ Canadian stock is currently split on opinions with one analyst, Matt Bottomley from Canaccord Genuity, recommending investors to sell, while Martin Landry’s latest report still has a “Buy” recommendation for investors.

A technical analysis summary on charting tool TradingView reveals a “Buy” recommendation as well.

Update from an Australian venture overseen by a Canadian operator stock

Investment company LGC Capital (TSXV:LG) announced Little Green Pharma, a private Australian company holding a license to grow medical cannabis, received a positive result from a mandatory inspection from a designated laboratory for medical cannabis tests.

This is one of the last steps before Little Green Pharma is allowed to sell its medical cannabis products. According to LGC, the products from the Australian producer will be tested for stability which the company estimates require close to a month and a half.

“The group to benefit most from this are patients and we are proud to be able to have our unique product offering available in August 2018,” Fleta Solomon, Little Green Pharma’s managing director said in a statement.

Little Green was also confirmed for a renewal of its medicinal cannabis license for the next two years by the Office of Drug Control (ODC) in the country, a development which John McMullen the CEO of LGC called a success. The new license will not expire until May 2020.

After completing its first ever harvest in April, the Australian producer is expecting its second harvest in eight to 10 weeks.

At the end of Tuesday’s trading session, LGC’s share price had increased 4.55 percent in value, reaching a price of C$0.12 per share.

The first half of 2018 has been volatile for LGC’s stock. Earlier in the year, the C$45.21 million market cap company reached some of its highest share price in years, hovering close to a C$1 price per share. However, since then the stock has seen a steady decrease up to its most recent closing price of C$0.11.

LGC increased its interest in the Australian venture to 14.99 percent by purchasing 2,283,495 shares of Little Green Pharma, at a price of AU$1.16398 per share. The total cost of the transaction, a little over C$2.6 million, was paid by way of issuing 5 million shares of LGC at a deemed price of C$0.53, the company’s closing price on January 19, 2018.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005322/en/

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (“ HempFusion ” or the “ Company ”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its wholly owned subsidiary, Probulin Probiotics, LLC (“ Probulin ”), has increased its product selection in certain brick and mortar locations and expanded its distribution on Amazon through a unique eCommerce store within the Amazon platform. The broader product selection is available in major brick and mortar stores including Sprouts and Fresh Thyme and includes the Company’s new Probulin Total Care Immune product.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005411/en/

Keep reading... Show less

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to report third party confirmatory studies that the active ingredient in MustGrow’s mustard plant-based technology, Allyl Isothiocyanate (“AITC”), has a positive impact on soil health, contributing to the environmental and ecological security of both our plant-based food supply and the planet. Application of natural AITC returns organic plant material to the soil through its pre-plant treatment process as a potential alternative to using synthetic chemicals.

Soil micro-organisms play an important role in soil fertility and plant health, contributing to natural soil processes including the formation of organic matter and nutrient transformation. Human activities, including chemical pesticide use, can adversely impact the soil microbial diversity and structure.

Keep reading... Show less

Heritage Cannabis Holdings Corp. (CSE: CANN) (OTCQX: HERTF) (“Heritage” or the “Company”), today announced that its subsidiary CannaCure Corp. (“CannaCure”) has entered into a binding letter of intent with Entourage Participações S.A. (“Entourage Phytolab”) for a three-year extraction and finished product supply agreement (the “Agreement”) for the distribution of pharmaceutical products in Brazil.

Under the terms of the Agreement, Heritage will supply to Entourage Phytolab, hemp-derived CBD dominant extract, cannabis-derived THC dominant extract, and hemp-derived CBD 25 mg softgels and cannabis-derived THC dominant 2.5 and 5.0 mg softgels.

Keep reading... Show less

Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) Is pleased to announce its partially owned subsidiary NeonMind (CSE: NEON) (“NeonMind”) has common shares now trading on the Frankfurt Stock Exchange (the “FSE”) under the symbol “6UF”. As a result, NeonMind’s common shares are now cross-listed on the Canadian Securities Exchange and the FSE. Shares of Better Plant are available on the FSE under the symbol “YG3”.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6377/72301_betterplanta.jpg

Keep reading... Show less